A detailed description of an intradermal test for the diagnosis of the drug responsible for acute anaphylactoid or anaphylactic reactions to anaesthetic drugs is presented. If intradermal testing is performed according to this protocol the drug responsible for the reaction can be determined in the majority of reactions.
In spite of a large number of published studies in which intradermal testing has been used to determine the drug responsible for an acute anaphylactoid reaction during anaesthesia there is still controversy over its diagnostic value, t safety,2 and whether it provides information about mechanism. 3 -5 I have previously published results of this form of testing in a large series of patients and shown that intradermal testing is more valuable in detecting the drug responsible for a reaction than other tests 6 and this has been confirmed by others. 7 -9 There is, in fact, no case in the literature where any other test has enabled the drug responsible to be determined when intradermal testing is negative.
Over the years a number of specific enquiries have been received from both within Australia and overseas regarding detailed methodology, interpretation and rationale of this form of testing and this paper is presented to clarify these questions.
A detailed description of the method follows: 1. Patients are tested as near as possible to one month after the reaction. 2. Patients should be off all drugs which may modify the response. Specific enquiry should be made about cough mixtures, cold tablets and nebulisers. Drugs which interfere with the response include antihistamines and sympathomimetics, and drugs which may interfere include theophyllines, steroids and disodium cromoglycate. 3 . The patients should be tested in or near an area where resuscitation facilities are available. We do not secure intravenous access prior to testing. 4. The drugs are diluted in normal saline immediately prior to testing. We use dilutions of the standard anaesthetic concentration of the drugs which are used in Australia. The initial dilution and final amount of drug are shown in Table 1 . 5. The method of dilution used is to clean the wall of a Viaflex® bag with isopropyl alcohol, label the bag, and inject the drug through the bag wall through a 21-gauge needle. The bag is agitated and left to stand for five minutes. The diluted drug is aspirated through the bag wall into labelled 1.0 ml syringes through a 19-9auge needle. The syringes are then capped with a 25or 26-gauge needle and the air expelled. 6. The patient is seated in a chair and one forearm exposed. Squares of one-inch sides are drawn on the arm with a blue Pentel® sign pen and labelled. The skin is lightly cleaned with isopropyl alcohol and the skin below the test area briskly rubbed with isopropyl alcohol to exclude sensitivity to the skin prep.
The drugs are injected intradermally into the centre of the appropriately labelled square. The injection is made with the needle bevel uppermost and the needle is introduced into the skin at a ten-degree angle until the central hole is covered. Sufficient solution is injected to raise a 1-2 mm weal (0.01-0.02 ml). (NOTE: In some previous descriptions it was incorrectly stated that 0.1 to 0.2 ml was used.) 7. If all tests are negative the drugs used at the time of anaesthesia are retested with the dilution increased and decreased tenfold. If any of these are positive, drugs of similar structure should be tested at these dilutions also. The patient is requested to report any changes in the sites over the next six hours. 8. Controls. (a) Control patients are no longer used in this department. The large number of patients tested have now led to a sufficient appreciation of the normal response. If a new drug is tested then a number of injections of serial dilutions of the drug must be used to determine that concentration of drug which does not produce a positive test in controls. Our practice usually involves testing more than one patient at a time, and patients can be used as their own controls. It is probably advisable for the "occasional operator" to use a control patient to observe the difference between the normal and the pathological response. 
Dilutions of drugs used in intradermal testing

Drug
Ampoule contents Dilution Quantity injected Alphaxalone 9 mg/ml Althesin Alphaxalone 3 mg/ml 1.0 ml in 100 ml Propanidid 500 mg in 10 ml 1.0 ml in 100 ml 5-10 /ig Diazepam 10 mg in 2 ml 1.0 ml in 100 ml 0.5-1 /ig Thiopentone 500 mg in 20 ml 1.0 ml in 100 ml 2.5-5 /ig Methohexitone 500 mg in 50 ml 1.0 ml in 100 ml 1-2 /ig Suxamethonium lOO mg in 2 ml 1.0 ml in 1,000 ml 5-10 /ig Decamethonium 1 mg/ml 1.0 ml in 1,000 ml 0.01-0.02/ig d-Tubocurarine 20 mg/2 ml 1.0 ml in 10,000 ml 1-2 /ig Alcuronium 10 mg in 2 ml 1.0 ml in 1,000 ml 0.5-1 /ig Pancuronium 4 mg in 2 ml 1.0 ml in 1,000 ml 0.2-0.4 /ig Gallamine 120 mg in 3 ml 1.0 ml in 1,000 ml 4-8/ig Atropine 0.6 mg in 1 ml 1.0 ml in 1,000 ml 0.04-0.08 /ig Neostigmine 2.5 mg in 1 ml 1.0 ml in 1,000 ml 0.25-0.5/ig Protamine 100 mg in 10 ml 1.0 ml in 10,000 ml 0. a weal and flare response in all patients, and may be used to determine whether negative tests to all drugs are due to impaired responsiveness. Patients on the drugs mentioned above and occasionally patients on cytotoxic drugs and radiotherapy may show an impaired response to the potent histamine-releasing action of morphine and d-tubocurarine, which means negative tests are unreliable. 9. Drugs Tested.
The method has been of no value for reactions to colloids, or contrast media in our hands although recently positive tests to modified gelatins have been described. to It should only be used for local anaesthetics as part of progressive challenge as advocated by de Shazo and Nelson.tt We have seen no positive responses in delayed reactions to thiopentone, and in minor reactions (e.g. urticaria or flushing) the test has limited use as concentrations which overlap with those producing positives in normal patients are necessary to get a response.
We no longer test additives, vehicles, antioxidants or preservatives separately with the exception of cremophor. Narcotics are very difficult to test as they are potent causes of false-positive reactions. There are no data available on the use of this form of testing for volatile agents which we suspect can cause such reactions.
It is not of value to include premedicant drugs unless the reaction occurs prior to induction. 10. Interpretation.
In our initial studies we regarded a positive response as a weal of greater than 1.5 cm and subsequently reduced that to 1.0 cm in diameter. The weal should arise within ten minutes and persist for at least 30 minutes. False-positive responses to direct histamine release will usually arise more rapidly and fade within twenty minutes. Subsequent experience has shown us that these criteria are too rigid and that other reliable criteria for a positive response occur. A weal of greater than 1.0 cm is generally accepted as a positive response in the allergy literature. However, in our experience other abnormal responses have been seen which we believe constitute valid and reliable criteria for a positive response: (a) Weals of greater than 7.0 mm. These are When testing is performed more than six months after the reaction the interpretation is difficult. Greater concentrations are necessary, and this increases the risk of false positives. 11. Drugs Used in Testing.
All the drugs used in the anaesthetic should be tested. In addition, if a reaction to althesin or propanidid occurs both should be tested. All muscle relaxants should be tested as crosssensitivity is common. When investigating possible reactions to local anaesthetics all types available should be tested.
RESULTS'
Over an eleven-year period we have used this method with minor variations in 286 patients. The variations consisted of an alteration in concentrations in 1978, and the abandoning of routine patient controls in 1979. For twelve months the results were read by an independent observer but there was no significant observer variation and this has also been abandoned.
The patient groups tested and frequency of positive results are shown in Table 2 .
DISCUSSION
Intradermal testing as outlined above is of great value in determining the drug responsible for an anaphylactoid reaction during anaesthesia. It may be that a more detailed protocol with serial dilutions of drugs as used by the French workers 5 would give more information but this method has the advantage of simplicity. The reliability of the method is decreased if testing is delayed longer than three months and if it is used to investigate reactions which are minor or delayed in onset.
At present the mechanism of the reactions and an idiosyncratic direct histamine-releasing effect cannot be excluded. This may be the great advantage of this form of testing as it appears to identify the drug responsible whether or not antibodies can be demonstrated. Irrespective of the mechanism of the reaction or the positive intradermal test it cannot be overemphasised that the reaction is drugspecific and will usually occur on subsequent exposure if the reaction is severe. A presence or absence of a history of previous 1xposure is likewise no guide as to mechanism.! A number of anaesthetists and allergists who have followed the above protocol have sought clarification of various aspects over the years and the following information is presented to clarify such requests. 1. The quoted dilutions of drug are used as they have been determined to provide an amount of drug which will not cause falsepositive reactions due to direct histamine release, 6 i.e. that will not produce weal and flare reactions in patients who have received the drug uneventfully.
2.
Testing is performed wherever possible at one month because the interpretation is more difficult as the interval between reaction and testing is increased. Although positive results have been obtained at 48 hours and 20 years there are theoretical objections to testing earlier than one month because of false negatives due to mediator depletion.
3. We have tested four families and three sets of twins and found no positive responses in those who had not reacted. There are no recorded cases of two members of a family reacting to anaesthetic drugs. 4. Some patients appear to have had minor reactions (transient bronchospasm, or hypotension) on previous occasions. Other patients have had minor reactions to a skin-testnegative relaxant after severe reactions to a skin-test-positive relaxant. No patient with a severe reaction has had a past history of skin changes and no patient with skin changes only has had a subsequent major reaction to the drug. However, it is logical to avoid drugs producing reactions and to investigate for positive tests to drugs of similar structure. 5. Two patients have had reactions to the tests. One patient developed tachycardia and a feeling of tightness in the chest and one patient developed hypotension and bronchospasm. Both patients responded rapidly (within minutes) to subcutaneous adrenaline. The tests are not absolutely safe but are almost certainly, AnaeSlhesia and IlItensive Care, Vol. 12, No. 2, May. 1984 safer than subsequent anaesthesia without investigation. 6. When patients show positive tests to all the relaxants it means that the patient is allergic to all the relaxants if the control test is negative. Such patients have been described 13 and this finding is probably due to the quaternary ammonium group being the antigenic part of the molecule. 14 7 . If all tests are negative the patients should be given a letter stating drugs given, nature of reaction and results of testing. With this information the anaesthetist still has a range of options such as regional block or inhalation anaesthesia. Of our patients with negative tests only one had a subsequent reaction which was a minor reaction to thiopentone after a convulsive reaction to propanidid. Two of the patients have been challenged with full doses of the drugs given at the time of reaction and had no adverse response.
One of our greatest concerns about these patients is that we cannot determine any reliable information about the volatile anaesthetics as aetiological agents in reactions. We believe, but have not sufficient data to prove, that patients who react via the alternative complement pathway and patients on radiotherapy and chemotherapy will have negative skin tests. In addition it is important to remember that negative tests to local anaesthesia followed by negative challenge may not be reliable for local anaesthetic solutions containing additives. 8. If one test is positive, drugs which give negative results are usually safe to administer, if all relaxants are tested. However, the interaction between the drugs is complex and the patient may rarely react to alternative drugs. It is possible, however, that if these reactions are an acquired sensitivity, that between testing and subsequent anaesthesia further sensitivities could be acquired. Alternative methods of anaesthesia should be considered and all resuscitation facilities available. In the presence of a prepared anaesthetist a second reaction is usually less severe as intervention is more rapid.
Intradermal testing has the advantages of being simple and requiring little expertise and no laboratory. If further tests, such as basophil degranulation or radioimmunoassay, are Anaesthesia al/d /lIfensi)'c Cure, Vol. 12. No, 2, A4ay, 1984 available, it is of value to perform them in addition to adding information about mechanism but such tests have not yet been shown to offer additional information about the drug responsible. If more than one drug is given prior to a reaction and intradermal testing is negative there is no way of determining the drug responsible. The demonstration of complement activation may incriminate a cremophor-based anaesthetic or protamine, but whether this activation occurs in reactions to muscle relaxants is not established.
After anaphylactoid reactions to anaesthetic drugs intradermal testing is the minimum investigation that should be performed. IS
